Drug intelligence / Profile preview

IFM-1222

Development stage: Unknown
Lead developer: IFM Therapeutics
Modality: Small Molecules

Overview

**IFM-1222** is a first-in-class small molecule agonist of the NLRP3 inflammasome, developed by IFM Therapeutics to activate the innate immune system. It was the initial compound in this class to dose a patient in February 2018, targeting NLRP3 to trigger inflammatory responses for potential therapeutic applications in immuno-oncology or infectious diseases, though specific indications remain undisclosed and no further development updates are available beyond initial dosing.[3][5]

Targets

NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on IFM-1222.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IFM-1222.

Explore the full profile